Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance

Overview

Journal Antioxid Redox Signal

Specialty Endocrinology

Date 2023 Apr 6

PMID 37022791

Authors

Justine Bailleul

Erina Vlashi

Affiliations

Soon will be listed here.

Abstract

Glioblastomas (GBMs) are among the most lethal tumors despite the almost exclusive localization to the brain. This is largely due to therapeutic resistance. Radiation and chemotherapy significantly increase the survival for GBM patients, however, GBMs always recur, and the median overall survival is just over a year. Proposed reasons for such intractable resistance to therapy are numerous and include tumor metabolism, in particular, the ability of tumor cells to reconfigure metabolic fluxes on demand (metabolic plasticity). Understanding how the hard-wired, oncogene-driven metabolic tendencies of GBMs intersect with flexible, context-induced metabolic rewiring promises to reveal novel approaches for combating therapy resistance. Personalized genome-scale metabolic flux models have recently provided evidence that metabolic flexibility promotes radiation resistance in cancer and identified tumor redox metabolism as a major predictor for resistance to radiation therapy (RT). It was demonstrated that radioresistant tumors, including GBM, reroute metabolic fluxes to boost the levels of reducing factors of the cell, thus enhancing clearance of reactive oxygen species that are generated during RT and promoting survival. The current body of knowledge from published studies strongly supports the notion that robust metabolic plasticity can act as a (flexible) shield against the cytotoxic effects of standard GBM therapies, thus driving therapy resistance. The limited understanding of the critical drivers of such metabolic plasticity hampers the rational design of effective combination therapies. Identifying and targeting regulators of metabolic plasticity, rather than specific metabolic pathways, in combination with standard-of-care treatments have the potential to improve therapeutic outcomes in GBM. 39, 957-979.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran M . PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep. 2016; 15(4):843-856. PMC: 5063668. DOI: 10.1016/j.celrep.2016.03.070. View

Owen O, Kalhan S, Hanson R . The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002; 277(34):30409-12. DOI: 10.1074/jbc.R200006200. View

Panov A, Orynbayeva Z, Vavilin V, Lyakhovich V . Fatty acids in energy metabolism of the central nervous system. Biomed Res Int. 2014; 2014:472459. PMC: 4026875. DOI: 10.1155/2014/472459. View

Maddocks O, Berkers C, Mason S, Zheng L, Blyth K, Gottlieb E . Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2012; 493(7433):542-6. PMC: 6485472. DOI: 10.1038/nature11743. View

Babic I, Anderson E, Tanaka K, Guo D, Masui K, Li B . EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013; 17(6):1000-1008. PMC: 3679227. DOI: 10.1016/j.cmet.2013.04.013. View

Singh D, Banerji A, Dwarakanath B, Tripathi R, Gupta J, Mathew T . Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005; 181(8):507-14. DOI: 10.1007/s00066-005-1320-z. View

Hitosugi T, Kang S, Vander Heiden M, Chung T, Elf S, Lythgoe K . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2(97):ra73. PMC: 2812789. DOI: 10.1126/scisignal.2000431. View

Laezza C, DAlessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S . p53 regulates the mevalonate pathway in human glioblastoma multiforme. Cell Death Dis. 2015; 6:e1909. PMC: 4632304. DOI: 10.1038/cddis.2015.279. View

10.

da-Silva W, Gomez-Puyou A, Tuena de Gomez-Puyou M, Moreno-Sanchez R, De Felice F, de Meis L . Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. J Biol Chem. 2004; 279(38):39846-55. DOI: 10.1074/jbc.M403835200. View

11.

Kostakoglu L, Agress Jr H, Goldsmith S . Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003; 23(2):315-40; quiz 533. DOI: 10.1148/rg.232025705. View

12.

Cosset E, Ilmjarv S, Dutoit V, Elliott K, Von Schalscha T, Camargo M . Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017; 32(6):856-868.e5. PMC: 5730343. DOI: 10.1016/j.ccell.2017.10.016. View

13.

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View

14.

Hassanein M, Qian J, Hoeksema M, Wang J, Jacobovitz M, Ji X . Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer. 2015; 137(7):1587-97. PMC: 4640891. DOI: 10.1002/ijc.29535. View

15.

Zhou W, Yao Y, Scott A, Wilder-Romans K, Dresser J, Werner C . Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020; 11(1):3811. PMC: 7393131. DOI: 10.1038/s41467-020-17512-x. View

16.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

17.

Xie Y, Lu Q, Lenahan C, Yang S, Zhou D, Qi X . Whether statin use improves the survival of patients with glioblastoma?: A meta-analysis. Medicine (Baltimore). 2020; 99(9):e18997. PMC: 7478415. DOI: 10.1097/MD.0000000000018997. View

18.

Li G, Wu J, Li L, Jiang P . p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage. Proc Natl Acad Sci U S A. 2021; 118(28). PMC: 8285905. DOI: 10.1073/pnas.2019822118. View

19.

Huppertz I, Perez-Perri J, Mantas P, Sekaran T, Schwarzl T, Russo F . Riboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation. Mol Cell. 2022; 82(14):2666-2680.e11. DOI: 10.1016/j.molcel.2022.05.019. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View